Last reviewed 2026-05-13 · How we verify

Topical travoprost 0.004% solution

Topical travoprost 0.004% solution, marketed by Assiut University, is a glaucoma treatment with a key composition patent expiring in 2028. The drug's market position is bolstered by its patented formulation, providing a competitive edge until the patent expiry. The primary risk is the potential increase in generic competition post-2028, which could erode market share and revenue.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension (PHASE2)
• Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents (PHASE4)
• Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo (PHASE4)
• Efficacy of Changing to DUOTRAV® From Prior Therapy (PHASE4)
• A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution
• Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension (PHASE4)
• Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Topical travoprost 0.004% solution CI brief — competitive landscape report
• Topical travoprost 0.004% solution updates RSS · CI watch RSS
• Assiut University portfolio CI